{'_data': [['Unknown',
            [['GI',
              u'Abdominal pain 3.7 3.0 6.6 4.8 Dyspepsia 2.7 2.2 3.6 3.5 Acid regurgitation 1.9 2.4 2.0 4.3 Nausea 1.9 2.4 3.6 4.0 Abdominal 1.0 1.4 1.0 0.8 distension Constipation 0.8 1.6 3.1 1.8 Diarrhoea 0.6 0.5 3.1 1.8 Dysphagia 0.4 0.5 1.0 0.0 Flatulence 0.4 1.6 2.6 0.5 Gastritis 0.2 1.1 0.5 1.3 Gastric ulcer 0.0 1.1 0.0 0.0 Oesophageal ulcer 0.0 0.0 1.5 0.0 Musculoskeletal Musculoskeletal 2.9 3.2 4.1 2.5 pain (bone, muscle or joints) Muscle cramps 0.2 1.1 0.0 1.0 Neurological Headache 0.4 0.3 2.6 1.5 The following adverse events have been reported in clinical studies and/or post marketing: Very common (\u2265 1/10), Common (\u2265 1/100 to < 1/10), Uncommon (\u2265 1/1,000 to < 1/100), Rare (\u2265 1/10,000 to < 1/1,000), Very rare (< 1/10,000 including isolated cases). Immune system disorders Rare Hypersensitivity reactions including urticaria and angioedema Nervous system disorders Common Headache, dizziness Uncommon Dysgeusia Eye disorders Uncommon Eye inflammation (uveitis, scleritis, episcleritis) Ear and labyrinth disorders Common Vertigo Gastrointestinal disorders Common Abdominal pain, dyspepsia, constipation, diarrhoea, flatulence, oesophageal ulcer*, dysphagia*, abdominal distension, acid regurgitation Uncommon Nausea, vomiting, gastritis, oesophagitis*, oesophageal erosions*, melaena Rare Oesophageal stricture*, oropharyngeal ulceration*, upper gastrointestinal PUBs (perforation, ulcers, bleeding) Skin and subcutaneous tissue disorders Common Alopecia , pruritus Uncommon Rash, erythema Rare Rash with photosensitivity, severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis Musculoskeletal and connective tissue disorders Very common Musculoskeletal (bone, muscle or joint) pain which is sometimes severe Common Joint swelling Rare Osteonecrosis of the jaw , atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction) \u22a5 Metabolism and nutrition disorders Rare Symptomatic hypocalcaemia, often in association with predisposing conditions General disorders and administration site conditions Common Asthenia , peripheral oedema Uncommon Transient symptoms as in an acute phase response (myalgia, malaise and rarely fever), typically in association with initiation of treatment see section 4.4 frequency in clinical trials was similar in the drug and placebo group. see sections 4.2 and 4.4 this adverse reaction was identified through post-marketing surveillance. The frequency of rare was estimated based on relevant clinical trials \u22a5 identified in postmarketing experience.']]]],
 '_pages': [6, 8],
 u'_rank': 1,
 u'_type': u'LSFU'}